https://clinicaltrials.gov/ct2/show/NCT03679598?type=Intr&cond=COPD&phase=01234&lupd_s=12%2F13%2F2018&lupd_d=14&sort=nwst Alvelestat (MPH996) for the Treatment of ALpha-1 ANTitrypsin Deficiency Conditions : Alpha-1 Antitrypsin Deficiency (AATD); Pi*ZZ, Pi*SZ, or Pi*Null Phenotype; Emphysema or COPD Interventions : Drug: Alvelestat (MPH996); Other: Placebo Sponsors : University of Alabama at Birmingham; National Institutes of Health (NIH); Mereo BioPharma Not yet recruiting NCT03679598 Thu, 20 Sep 2018 12:00:00 EDT >>> updated dec 18, 2018
Alvelestat
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo
https://clinicaltrials.gov/ct2/show/NCT03636347?type=Intr&cond=COPD&phase=01234&lupd_s=11%2F01%2F2018&lupd_d=14&sort=nwst A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo. Conditions : Alpha 1-Antitrypsin Deficiency; Emphysema; COPD Interventions : Drug: Placebo Oral Tablet; Drug: Alvelestat oral tablet – dose 1; Drug: Alvelestat oral tablet – dose 2 Sponsors : Mereo BioPharma; Syneos Health Recruiting NCT03636347 Fri, 17 Aug 2018 12:00:00 EDT